The problems in scaling adult drug doses to children

Archives of Disease in Childhood

Volumn 93, Issue 3, 2008, Pages 207-211

  Johnson, T N ^a  

^a SHEFFIELD CHILDREN S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AMOXICILLIN; ATENOLOL; CAPTOPRIL; CEFOTAXIME; CIMETIDINE; CIPROFLOXACIN; CLOBAZAM; CODEINE; DIAZEPAM; DICLOFENAC; DOMPERIDONE; FLUCONAZOLE; FUROSEMIDE; GABAPENTIN; GENTAMICIN; IBUPROFEN; METRONIDAZOLE; MORPHINE; NIFEDIPINE; OMEPRAZOLE; PARACETAMOL; PENICILLIN G; PHENOBARBITAL; PHENYTOIN; PROPRANOLOL; PYRAZINAMIDE; RIFAMPICIN; UNINDEXED DRUG; VANCOMYCIN; DRUG;

ACCURACY; ALLOMETRY; ANAEROBIC INFECTION; ANALGESIA (SENSORY DYSFUNCTION); ANALYTICAL ERROR; ANTIBIOTIC THERAPY; ARTICLE; BASAL METABOLIC RATE; BODY SIZE; BODY SURFACE; BODY WEIGHT; DOSE CALCULATION; DRUG CLEARANCE; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG FORMULARY; EDEMA; EPILEPSY; FOCAL EPILEPSY; GROUPS BY AGE; HEART ARRHYTHMIA; HERPES ZOSTER; HUMAN; HYPERTENSION; MAINTENANCE DRUG DOSE; MENINGITIS; MUSCLE SPASM; MYCOSIS; NAUSEA AND VOMITING; PREDICTION; PRIORITY JOURNAL; REFLUX ESOPHAGITIS; TUBERCULOSIS; ADULT; AGE; ALGORITHM; CHILD; INFANT;

ADULT; AGE FACTORS; ALGORITHMS; BODY SURFACE AREA; BODY WEIGHT; CHILD; DRUG DOSAGE CALCULATIONS; HUMANS; INFANT; PHARMACEUTICAL PREPARATIONS;

EID: 41749105125     PISSN: 00039888     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/adc.2006.114835     Document Type: Article

References (26)

1. Conroy S, Choonara I, Impicciatore P, et al. Survey of unlicensed and off label drug use in paediatric wards in European countries. European Network for Drug Investigation in Children. BMJ 2000;320:79-82
2. Mclntyre J, Conroy S, Avery A, et al. Unlicensed and off label prescribing of drugs in general practice. Arch Dis Child 2000;83:498-501.
3. Horen B, Montastruc JL, Lapeyre-Mestre M. Adverse drug reactions and off-label drug use in paediatric outpatients. Br J Clin Pharmacol 2002;54:665-70
4. Turner S, Nunn AJ, Fielding K, et al. Adverse drug reactions to unlicensed and off-label drugs on paediatric wards: a prospective study. Acta Paediatr 1999;88:965-8
5. British Medical Association, Royal College of Paediatrics and Child Health, Royal Pharmaceutical Society of Great Britain. BNF for children. London: BMJ Publishing Group. RPS publishing. RCPCH publications, 2006.
6. Neonatal and Paediatric Pharmacists Group (NPPG) www.nppg.org.uk/ (accessed 23 Feb 2007).
7. Dial: NHS Paediatric Medicines Information Advisory Line www dial org uk/ (accessed 23 Feb 2007).
8. National Electronic Library for Medicines (NELM). www.nelm.nhs.uk (accessed 23 Feb 2007).
9. emedicine. www.emedicine.com (accessed 23 Feb 2007).
10. Anderson BJ, Meakin GH. Scaling for size: some implications for paediatric anaesthesia dosing. Paediatr Anaesth 2002;12:205-19.
11. West GB, Brown JH, Enquist BJ. A general model for the origin of allometric scaling laws in biology. Science 1997;276:122-6.
12. British Medical Association, Royal Pharmaceutical Society of Great Britain. British National Formulary. London: BMJ Books, Pharmaceutical Press, 2006.
13. ICH (International Conference on Harmonisation). 2000. Clinical Investigation of Medicinal Products in the Pediatric Population: E11. Geneva, Switzerland.http:// www.ich/L0B/media/MEDIA487.pdf (accessed 19 Feb 2007).
14. Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. Pharmacokinet Biopharm 1981;9:503-12.
15. Mahmood I. Prediction of drug clearance in children from adults: a comparison of several allometric methods. Br J Clin Pharmacol 2006;61:545-57.
16. Anderson BJ, Ellis JF. Common errors of drug administration in infants: causes and avoidance. Paediatr Drugs 1999;1:93-107.
17. Holford NH. A size standard for pharmacokinetics. Clin Pharmacokinet 1996;30:329-32.
18. European Commission. Better medicines for children: proposed regulatory actions on paediatric medicinal products, 2002. http://www.fda.gov/ opacom/laws/ pharmkids/contents.html (accessed 9 Jan 2008).
19. US Congress. 1st Session. Best Pharmaceuticals for children act. Public Law 107-109, 2002.
20. Pelekis M, Gephart LA, Lerman SE. Physiological-model-based derivation of the adult and child pharmacokinetic intraspecies uncertainty factors for volatile organic compounds. Regul Toxicol Pharmacol 2001;33:12-20.
21. Price K, Haddad S, Krishnan K. Physiological modeling of age-specific changes in the pharmacokinetics of organic chemicals in children. J Toxicol Environ Health A 2003;66:417-33.
22. Gentry PR, Covington TR, Clewell HJ 3rd. Evaluation of the potential impact of pharmacokinetic differences on tissue dosimetry in offspring during pregnancy and lactation. Regul Toxicol Pharmacol 2003;38:1-16.
23. Bjorkman S. Prediction of drug disposition in infants and children by means of physiologically based pharmacokinetic (PBPK) modelling: theophylline and midazolam as model drugs. Br J Clin Pharmacol 2005;59:691-704.
24. Ginsberg G, Hattis D, Russ A, et al. Physiologically based pharmacokinetic (PBPK) modeling of caffeine and theophylline in neonates and adults: implications for assessing children's risks from environmental agents. J Toxicol Environ Health A 2004;67:297-329.
25. Johnson TN, Rostami-Hodjegan A, Tucker GT. Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children. Clin Pharmacokinet 2006;45:931-56.
26. Johnson TN. Modelling approaches to dose estimation in children. Br J Clin Pharmacol 2005;59:663-9.